Lakefront Biotherapeutics NV ADR (LKFT)

Currency in USD
29.67
+0.19(+0.64%)
Closed·
29.670.00(0.00%)
·
LKFT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
29.1929.73
52 wk Range
26.4237.78
Key Statistics
Prev. Close
29.48
Open
29.59
Day's Range
29.19-29.73
52 wk Range
26.42-37.78
Volume
122.62K
Average Volume (3m)
170.59K
1-Year Change
6.0021%
Book Value / Share
57.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LKFT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.89
Downside
-22.86%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

0 Buy
3 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 22.89
(-22.86% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Lakefront Biotherapeutics NV ADR Earnings Call Summary for Q1/2026

  • Galapagos Q1 2026 EPS of $0.25 beat estimates by 126%, but revenue of $7.6M missed forecasts by 77% due to absent legacy OLCA revenue.
  • Operating loss improved 60% YoY to $63.7M; net profit swung to $14.5M from $153.4M loss, driven by cost management and FX gains.
  • Company holds $2.98B cash with 20.15 current ratio; Ouro Medicines transaction expected to close Q2 2026 with significant cash outlay.
  • Stock declined 0.42% premarket; EPS projections remain negative through FY2027 despite strategic transformation efforts underway.
  • CEO emphasized cost reduction success and Gamgertamig pipeline potential; management confident in competitive positioning amid revenue volatility.
Last Updated: 2026-05-07, 08:46 a/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
0.25 / -0.95
Revenue / Forecast
7.63M / 33.59M
EPS Revisions
Last 90 days

LKFT Income Statement

Compare LKFT to Peers and Sector

Metrics to compare
LKFT
Peers
Sector
Relationship
P/E Ratio
3.5x16.1x−0.4x
PEG Ratio
0.010.220.00
Price/Book
0.5x3.8x2.6x
Price / LTM Sales
1.6x5.0x3.0x
Upside (Analyst Target)
−22.6%19.7%51.8%
Fair Value Upside
Unlock4.8%7.2%Unlock

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.89M11.97%232.62M
Other Institutional Investors
50.22M76.21%1.48B
Public Companies & Retail Investors
7.79M11.81%229.50M
Total
65.9M100.00%1.94B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Gilead Sciences, Inc.25.35%16,707,477492,536
Ecor1 Capital Fund Qualified, L.P.12.43%8,192,077241,502

People Also Watch

314.04
LGND
+3.44%
49.76
MTDR
-0.28%
7.740
XERS
+0.65%
122.76
DAC
-0.21%

FAQ

What Is the Lakefront Bio ADR (LKFT) Stock Price Today?

The Lakefront Bio ADR stock price today is 29.67 USD.

What Stock Exchange Does Lakefront Bio ADR Trade On?

Lakefront Bio ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Lakefront Bio ADR?

The stock symbol for Lakefront Bio ADR is "LKFT."

What Is the Lakefront Bio ADR Market Cap?

As of today, Lakefront Bio ADR market cap is 1.93B USD.

What Is Lakefront Bio ADR's Earnings Per Share (TTM)?

The Lakefront Bio ADR EPS (TTM) is 7.40.

When Is the Next Lakefront Bio ADR Earnings Date?

Lakefront Bio ADR will release its next earnings report on Aug 10, 2026.

From a Technical Analysis Perspective, Is LKFT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Lakefront Bio ADR Stock Split?

Lakefront Bio ADR has split 0 times.

How Many Employees Does Lakefront Bio ADR Have?

Lakefront Bio ADR has 704 employees.

What is the current trading status of Lakefront Bio ADR (LKFT)?

As of Jun 30, 2026, Lakefront Bio ADR (LKFT) is trading at a price of 29.67 USD, with a previous close of 29.48 USD. The stock has fluctuated within a day range of 29.19 USD to 29.73 USD, while its 52-week range spans from 26.42 USD to 37.78 USD.

What Is Lakefront Bio ADR (LKFT) Price Target According to Analysts?

The average 12-month price target for Lakefront Bio ADR is 22.89 USD, with a high estimate of 27.1448103 USD and a low estimate of 18.62823288 USD. 0 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -22.86% Downside potential.

What Is the LKFT Premarket Price?

LKFT's last pre-market stock price is 29.59 USD. The pre-market share volume is 690.00, and the stock has decreased by 0.11, or 0.37%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.